Kalydeco

Kalydeco (ivacaftor) is a medication designed to improve the function of the CFTR protein in people with cystic fibrosis caused by specific genetic mutations. In cystic fibrosis, faulty CFTR proteins lead to thick, sticky mucus buildup in lungs and organs. Kalydeco works by enhancing the activity of these proteins, helping to restore normal salt and water flow. This can improve lung function, reduce coughing, and decrease infection risk. It is tailored for certain genetic profiles and is part of personalized medicine approaches, helping manage symptoms and improve quality of life for eligible patients.